Register for our free email digests:
Latest From Janssen Pharmaceuticals Inc.
WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
Johnson & Johnson's combination HIV therapy Symtuza has secured a greenlight in Europe, marking its first approval worldwide – but will the big pharma be able to catch up with successful HIV opponents from AbbVie and Gilead?
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Apexigen Inc.
- Senior Management
Xiaodong Yang, MD, PhD, Pres. & CEO
Mark Nevins, VP, Bus. Dev.
Amy Wong, VP, Finance
Ovid C Triffan, MD, PhD, CMO
- Contact Info
Phone: (650) 931-6236
75 Shoreway Rd.
San Carlos, CA 94070
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.